- Research article
- Open Access
Evaluating the association of common APOA2variants with type 2 diabetes
BMC Medical Genetics volume 10, Article number: 13 (2009)
APOA2 is a positional and biological candidate gene for type 2 diabetes at the chromosome 1q21-q24 susceptibility locus. The aim of this study was to examine if HapMap phase II tag SNPs in APOA2 are associated with type 2 diabetes and quantitative traits in French Caucasian subjects.
We genotyped the three HapMap phase II tagging SNPs (rs6413453, rs5085 and rs5082) required to capture the common variation spanning the APOA2 locus in our type 2 diabetes case-control cohort comprising 3,093 French Caucasian subjects. The association between these variants and quantitative traits was also examined in the normoglycaemic adults of the control cohort. In addition, meta-analysis of publicly available whole genome association data was performed.
None of the APOA2 tag SNPs were associated with type 2 diabetes in the French Caucasian case-control cohort (rs6413453, P = 0.619; rs5085, P = 0.245; rs5082, P = 0.591). However, rs5082 was marginally associated with total cholesterol levels (P = 0.026) and waist-to-hip ratio (P = 0.029). The meta-analysis of data from 12,387 subjects confirmed our finding that common variation at the APOA2 locus is not associated with type 2 diabetes.
The available data does not support a role for common variants in APOA2 on type 2 diabetes susceptibility or related quantitative traits in Northern Europeans.
The APOA2 gene is located at chromosome 1q23.3, within the 1-LOD support interval of several genome-wide linkage scans for type 2 diabetes [1–3]. The peak of linkage in the French and Utah Caucasian genome-wide linkage scans was defined by the APOA2 intragenic microsatellite D1SAPO2 [1, 3]. APOA2 encodes the apolipoprotein (apo) A-II, the second most abundant protein of the high-density lipoprotein (HDL) particles [4, 5].
Transgenic mice overexpressing human APOA2 on a standard chow diet displayed lipid profiles similar to that seen in human type 2 diabetes [6, 7]. Moreover, plasma human apoA-II levels were positively correlated with blood glucose levels and these animals displayed impaired glucose tolerance . In the human HepG2 cell line and in rat primary hepatocytes, transcription of the human APOA2 transgene was upregulated by glucose in a HNF-4á-dependent fashion, whereas in streptozotocin-induced diabetic rats Apoa2 mRNA levels were not affected .
Overexpression of mouse Apoa2 contrastingly resulted in elevated levels of HDL and fasting blood glucose levels that were not significantly different from normal [8–10]. However, these mice appeared to be in a state of insulin resistance exhibiting two-fold raised plasma insulin levels, decreased triglyceride hydrolysis and increased fat deposition in adipose tissue, as well as delayed glucose clearance due to slower uptake in skeletal muscle . Taken together, these findings point to a primary lipoprotein disturbance causing the development of several features of insulin resistance.
On the other hand, homozygous Apoa2 null-mice had HDL level reductions of 70%, as well as lower free fatty acid, glucose and insulin levels, suggesting they may be insulin hypersensitive .
Previous genetic analysis of APOA2in type 2 diabetes
Elbein and colleagues tested four APOA2 variants for association with T2D by TDT in 698 family members and in a very small case-control cohort of 247 subjects . None of the SNPs exhibited association with T2D in the case-control cohort, nor were any of the SNP alleles over-transmitted in the TDT analysis. Certain microsatellite alleles, however, indicated a trend for excess transmission to diabetic patients and marginal association with triglyceride levels, FFA and fasting glucose, as well as first phase insulin response and insulin deposition index in model analysis .
All subjects were of French Caucasian ancestry. Individuals identified by Sladek et al.  to lie outside the HapMap CEU ancestry cluster were excluded from the study. Type 2 diabetic case subjects were known diabetic patients receiving treatment for the condition. Normoglycaemic control subjects were selected to have a fasting blood glucose concentration <6.1 mM . Case subjects were composed of: (i) 372 probands from diabetic families , recruited in Lille; and (ii) 1083 patients with a family history of T2D recruited at the Corbeil-Essonne Hospital. Control subjects were composed of: (i) 353 normoglycaemic parents from T2D families; (ii) 543 subjects from the SUVIMAX (Supplementation en Vitamines et Minéraux Antioxidant) prospective population-based cohort study ; and (iii) 742 subjects selected from the DESIR (Data from an Epidemiologic Study on the Insulin Resistance Syndrome) cohort, a large prospective study of insulin resistance in French subjects . Informed consent was obtained from all subjects and the study was approved by the local ethics committees.
The case-control cohort comprised 1,455 type 2 diabetic subjects (age, 60 ± 12 years; BMI, 29.0 ± 6.0 kg/m2; male/female, 56:44%) and 1,638 normoglycaemic subjects (age, 54 ± 13 years; BMI, 24.1 ± 3.3 kg/m2; male/female, 43:57%). At α = 0.05, this sample size provided 91% power  to detect a type 2 diabetes susceptibility variant, assuming an allele frequency of 0.20, a disease prevalence of 0.1 and a heterozygote relative risk of 1.2 (multiplicative model).
APOA2tag SNP selection
The genomic target region for tag SNP selection extended across the 3 kb NCBI36 APOA2 locus (chr1:159,458,001..159,461,000). A total of three HapMap phase II pairwise tagging SNPs (rs6413453, rs5085 and rs5082) were sufficient to tag the common variation across the APOA2 locus (HapMap Data Release 22/Apr07) with r2 and minor allele frequency (MAF) thresholds of 0.9 and 0.05, respectively.
Genotyping was performed with the Sequenom MassARRAY iPLEX system . SNP genotype frequencies were tested for accordance with Hardy-Weinberg equilibrium using chi-squared analysis. Quality control: all genotyped SNPs exhibited a call rate >99% and a Hardy-Weinberg P > 0.05, with well defined genotype clusters. In total, 19 case and 42 control subjects (1.97% of the total sample size) consistently failed genotyping and were removed from further analysis.
To test for association of APOA2 SNPs with type 2 diabetes, chi-squared analysis of allele and genotype counts was performed. Pairwise SNP linkage disequilibrium (LD) values were calculated from the genotype data of the control cohort with Haploview (4.0) . Quantitative anthropomorphic phenotypes, body mass index (BMI), weight and waist-hip ratio (WHR), as well as fasting serum levels of glucose, insulin, triacylglycerol (TG), total and high-density lipoprotein (HDL)-cholesterol, apolipoprotein A-I (APOA1) and apolipoprotein B (APOB), measured in 1,539 normoglycaemic subjects from the control cohort, were log transformed and adjusted for age, sex and BMI, as appropriate. SNPs were tested for association with adjusted quantitative traits using SPSS 15.0 with the ANOVA test under a codominant model. Quantitative trait association p-values are presented uncorrected for multiple testing. Combined analysis of association datasets was carried out by pooling of log-transformed odds ratios with the inverse variance method for the fixed-effects and random-effects models. The DIAGRAM  data included a sib-ship component from the DGI GWAS ; however, due to uncertainties about controlling for the effects of the relatedness of part of the study sample, we excluded these subjects and obtained data solely for unrelated subjects from the authors (E. Zeggini, personal communication, 23/04/2008). Inter-study heterogeneity was assessed with Cochran's Q statistic and the I2 metric . These calculations were performed using R (2.5.1) statistical software .
None of the three genotyped APOA2 tag SNPs showed evidence for association (P < 0.05) with type 2 diabetes in this French Caucasian cohort (Table 1; genotype counts see Additional file 1: Additional table 1). This finding is in agreement with the French GWAS , as well as a recent meta-analysis  of the DGI , FUSION  and WTCCC  genome-wide association studies.
Quantitative trait associations
The APOA2 promoter SNP rs5082 was marginally associated with total cholesterol levels (P = 0.026) and waist-to-hip ratio (P = 0.029) (Table 2), and both associations exhibited a linear increase of the value of the quantitative phenotype from the common homozygote to the rare homozygote allele carriers (Table 3). The intronic variant rs6413453 was marginally associated with weight (P = 0.049), but given the small number of homozygote carriers of the minor allele (n = 13), it is likely that this is a spurious result (Table 2).
Linkage disequilibrium structure of the APOA2genomic locus
The structure of linkage disequilibrium across the three tag SNPs studied was consistent with HapMap phase II data. The levels of intermarker LD (r2) were negligible for the APOA2 locus (Additional file 1: Additional table 2). Therefore, no haplotype analysis was performed for APOA2 variants.
Meta-analysis of APOA2variants
Meta-analysis combining publicly available data with our current study confirmed in over 12,000 subjects that none of the APOA2 tag SNPs were associated with type 2 diabetes (Additional files 2, 3, 4) and there appeared to be no study heterogeneity (Cochran's Q: P > 0.72; I2 = 0% for all variants). Consistent with the absence of inter-study heterogeneity the fixed and random effects models were identical for all three variants, therefore only the fixed effects are displayed.
The APOA2 gene appeared to be a highly plausible candidate gene for type 2 diabetes susceptibility. In addition to defining the peak of linkage at chromosome 1q in French and Utah Caucasian families, APOA2 is the second most abundant lipoprotein component of HDL-cholesterol and has been implicated in the regulation of lipid metabolism and insulin sensitivity.
Three HapMap phase II tag SNPs suffice to cover the common variation spanning APOA2 and genotyping of these variants demonstrated no association with type 2 diabetes. However, we cannot rule out the possibilities that distal common variants or rare APOA2 variants may be associated with type 2 diabetes. The quantitative trait association for the APOA2 variant rs5082 with total cholesterol levels was consistent with the physiological role of apoA-II; however, the strength of the association was marginal, as were the remaining, weaker associations with other continuous traits.
Meta-analysis of our data with DIAGRAM  consortium data, which was a mixture of directly genotyped and imputed SNPs (Table 1), corroborated our findings of no association with type 2 diabetes. It was also welcome to note that the data from imputed SNPs were in this context indistinguishable from that of the directly genotyped variants.
Using a case-control cohort of over 3,000 subjects, we tested HapMap phase II tag SNPs that capture the common variation spanning the APOA2 genomic locus for association with type 2 diabetes, but failed to find any evidence supporting a contribution of this locus to type 2 diabetes susceptibility. This finding was confirmed in a combined analysis of more than 12,000 subjects.
Diabetes Genetics Initiative
Diabetes Genetics Replication And Meta-analysis
free fatty acids
Finland-United States Investigation of NIDDM Genetics
Genome-wide association study
Genome-wide association study meta-analysis
Wellcome Trust Case-Control Consortium.
Elbein SC, Hoffman MD, Teng K, Leppert MF, Hasstedt SJ: A genome-wide search for type 2 diabetes susceptibility genes in Utah Caucasians. Diabetes. 1999, 48: 1175-1182. 10.2337/diabetes.48.5.1175.
Hanson RL, Ehm MG, Pettitt DJ, Prochazka M, Thompson DB, Timberlake D, Foroud T, Kobes S, Baier L, Burns DK, Almasy L, Blangero J, Garvey WT, Bennett PH, Knowler WC: An autosomal genomic scan for loci linked to type II diabetes mellitus and body-mass index in Pima Indians. Am J Hum Genet. 1998, 63: 1130-1138. 10.1086/302061.
Vionnet N, Hani El H, Dupont S, Gallina S, Francke S, Dotte S, De Matos F, Durand E, Lepretre F, Lecoeur C, Gallina P, Zekiri L, Dina C, Froguel P: Genomewide search for type 2 diabetes-susceptibility genes in French whites: evidence for a novel susceptibility locus for early-onset diabetes on chromosome 3q27-qter and independent replication of a type 2-diabetes locus on chromosome 1q21-q24. Am J Hum Genet. 2000, 67: 1470-1480. 10.1086/316887.
Borghini I, James RW, Blatter MC, Pometta D: Distribution of apolipoprotein E between free and A-II complexed forms in very-low- and high-density lipoproteins: functional implications. Biochim Biophys Acta. 1991, 1083: 139-146.
Weisgraber KH, Mahley RW: Apoprotein (E-A-II) complex of human plasma lipoproteins. I. Characterization of this mixed disulfide and its identification in a high density lipoprotein subfraction. J Biol Chem. 1978, 253: 6281-6288.
Boisfer E, Lambert G, Atger V, Tran NQ, Pastier D, Benetollo C, Trottier JF, Beaucamps I, Antonucci M, Laplaud M, Griglio S, Chambaz J, Kalopissis AD: Overexpression of human apolipoprotein A-II in mice induces hypertriglyceridemia due to defective very low density lipoprotein hydrolysis. J Biol Chem. 1999, 274: 11564-11572. 10.1074/jbc.274.17.11564.
Sauvaget D, Chauffeton V, Dugue-Pujol S, Kalopissis AD, Guillet-Deniau I, Foufelle F, Chambaz J, Leturque A, Cardot P, Ribeiro A: In vitro transcriptional induction of the human apolipoprotein A-II gene by glucose. Diabetes. 2004, 53: 672-678. 10.2337/diabetes.53.3.672.
Castellani LW, Goto AM, Lusis AJ: Studies with apolipoprotein A-II transgenic mice indicate a role for HDLs in adiposity and insulin resistance. Diabetes. 2001, 50: 643-651. 10.2337/diabetes.50.3.643.
Hedrick CC, Castellani LW, Warden CH, Puppione DL, Lusis AJ: Influence of mouse apolipoprotein A-II on plasma lipoproteins in transgenic mice. J Biol Chem. 1993, 268: 20676-20682.
Warden CH, Hedrick CC, Qiao JH, Castellani LW, Lusis AJ: Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II. Science. 1993, 261: 469-472. 10.1126/science.8332912.
Weng W, Breslow JL: Dramatically decreased high density lipoprotein cholesterol, increased remnant clearance, and insulin hypersensitivity in apolipoprotein A-II knockout mice suggest a complex role for apolipoprotein A-II in atherosclerosis susceptibility. Proc Natl Acad Sci USA. 1996, 93: 14788-14794. 10.1073/pnas.93.25.14788.
Elbein SC, Chu W, Ren Q, Wang H, Hemphill C, Hasstedt SJ: Evaluation of apolipoprotein A-II as a positional candidate gene for familial Type II diabetes, altered lipid concentrations, and insulin resistance. Diabetologia. 2002, 45: 1026-1033. 10.1007/s00125-002-0850-5.
Sladek R, Rocheleau G, Rung J, Dina C, Shen L, Serre D, Boutin P, Vincent D, Belisle A, Hadjadj S, Balkau B, Heude B, Charpentier G, Hudson TJ, Montpetit A, Pshezhetsky AV, Prentki M, Posner BI, Balding DJ, Meyre D, Polychronakos C, Froguel P: A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature. 2007, 445: 881-885. 10.1038/nature05616.
American Diabetes Association: Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2003, 26 (Suppl 1): S5-20.
Hercberg S, Preziosi P, Briancon S, Galan P, Triol I, Malvy D, Roussel AM, Favier A: A primary prevention trial using nutritional doses of antioxidant vitamins and minerals in cardiovascular diseases and cancers in a general population: the SU.VI.MAX study – design, methods, and participant characteristics. SUpplementation en VItamines et Mineraux AntioXydants. Control Clin Trials. 1998, 19: 336-351. 10.1016/S0197-2456(98)00015-4.
Balkau B: [An epidemiologic survey from a network of French Health Examination Centres, (D.E.S.I.R.): epidemiologic data on the insulin resistance syndrome]. Rev Epidemiol Sante Publique. 1996, 44: 373-375.
Purcell S, Cherny SS, Sham PC: Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics. 2003, 19: 149-150. 10.1093/bioinformatics/19.1.149.
Jurinke C, Boom van den D, Cantor CR, Koster H: Automated genotyping using the DNA MassArray technology. Methods in Molecular Biology. 2002, 187: 179-192.
Barrett JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005, 21: 263-265. 10.1093/bioinformatics/bth457.
Zeggini E, Scott L, Saxena R, Voight B, for the DIAGRAM Consortium: Meta-analysis of genome-wide association data and large-scale replication identifies several additional susceptibility loci for type 2 diabetes. Nat Genet. 2008, 40 (5): 638-645. 10.1038/ng.120.
Saxena R, Voight BF, Lyssenko V, Burtt NP, de Bakker PI, Chen H, Roix JJ, Kathiresan S, Hirschhorn JN, Daly MJ, Hughes TE, Groop L, Altshuler D, Almgren P, Florez JC, Meyer J, Ardlie K, Bengtsson Bostrom K, Isomaa B, Lettre G, Lindblad U, Lyon HN, Melander O, Newton-Cheh C, Nilsson P, Orho-Melander M, Rastam L, Speliotes EK, Taskinen MR, Tuomi T, Guiducci C, Berglund A, Carlson J, Gianniny L, Hackett R, Hall L, Holmkvist J, Laurila E, Sjogren M, Sterner M, Surti A, Svensson M, Svensson M, Tewhey R, Blumenstiel B, Parkin M, Defelice M, Barry R, Brodeur W, Camarata J, Chia N, Fava M, Gibbons J, Handsaker B, Healy C, Nguyen K, Gates C, Sougnez C, Gage D, Nizzari M, Gabriel SB, Chirn GW, Ma Q, Parikh H, Richardson D, Ricke D, Purcell S: Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science. 2007, 316: 1331-1336. 10.1126/science.1142358.
Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. Bmj. 2003, 327: 557-560. 10.1136/bmj.327.7414.557.
R Development Core Team: R: A Language and Environment for Statistical Computing. 2007, Vienna, Austria: R Foundation for Statistical Computing
Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, Duren WL, Erdos MR, Stringham HM, Chines PS, Jackson AU, Prokunina-Olsson L, Ding CJ, Swift AJ, Narisu N, Hu T, Pruim R, Xiao R, Li XY, Conneely KN, Riebow NL, Sprau AG, Tong M, White PP, Hetrick KN, Barnhart MW, Bark CW, Goldstein JL, Watkins L, Xiang F, Saramies J, Buchanan TA, Watanabe RM, Valle TT, Kinnunen L, Abecasis GR, Pugh EW, Doheny KF, Bergman RN, Tuomilehto J, Collins FS, Boehnke M: A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science. 2007, 316: 1341-1345. 10.1126/science.1142382.
Zeggini E, Weedon MN, Lindgren CM, Frayling TM, Elliott KS, Lango H, Timpson NJ, Perry JR, Rayner NW, Freathy RM, Barrett JC, Shields B, Morris AP, Ellard S, Groves CJ, Harries LW, Marchini JL, Owen KR, Knight B, Cardon LR, Walker M, Hitman GA, Morris AD, Doney AS, McCarthy MI, Hattersley AT: Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science. 2007, 316: 1336-1341. 10.1126/science.1142364.
The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2350/10/13/prepub
This work was supported by a Wellcome Trust University Award to F.G. (GR065414MF) and a Medical Research Council Program Grant to PF (G0000477). We thank the referees for critically appraising draft versions of the manuscript.
The authors declare that they have no competing interests.
KD participated in the design of the study, carried out the SNP genotyping, performed the analysis of the genotype data and drafted the manuscript. GC, MM, JT, SH and BB contributed to the design of the study. PF contributed to the study design and to drafting of the manuscript. FG contributed to the design of the study, the analysis of the genotype data and in drafting the manuscript. All authors read and approved the final manuscript.
Electronic supplementary material
Additional file 1: Additional tables 1 and 2. Word document containing a a table listing the genotype counts for each SNP and a tabular representation of the LD structure across the locus. (DOC 37 KB)
About this article
Cite this article
Duesing, K., Charpentier, G., Marre, M. et al. Evaluating the association of common APOA2variants with type 2 diabetes. BMC Med Genet 10, 13 (2009). https://doi.org/10.1186/1471-2350-10-13
- APOA2 Gene
- Diabetes Susceptibility
- HapMap Phase
- Impute SNPs
- APOA2 Locus